HUMD.F logo

Hua Medicine (Shanghai) OTCPK:HUMD.F Stock Report

Last Price

US$0.15

Market Cap

US$193.1m

7D

0%

1Y

n/a

Updated

22 Dec, 2024

Data

Company Financials

Hua Medicine (Shanghai) Ltd.

OTCPK:HUMD.F Stock Report

Market Cap: US$193.1m

HUMD.F Stock Overview

Operates as a drug development company that focuses on therapies for the treatment of diabetes in China. More details

HUMD.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Hua Medicine (Shanghai) Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hua Medicine (Shanghai)
Historical stock prices
Current Share PriceHK$0.15
52 Week HighHK$0.15
52 Week LowHK$0.15
Beta1.45
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-70.00%

Recent News & Updates

Recent updates

Shareholder Returns

HUMD.FUS PharmaceuticalsUS Market
7D0%-1.5%-2.4%
1Yn/a7.9%23.4%

Return vs Industry: Insufficient data to determine how HUMD.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HUMD.F performed against the US Market.

Price Volatility

Is HUMD.F's price volatile compared to industry and market?
HUMD.F volatility
HUMD.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: HUMD.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine HUMD.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011172Li Chenwww.huamedicine.com

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease.

Hua Medicine (Shanghai) Ltd. Fundamentals Summary

How do Hua Medicine (Shanghai)'s earnings and revenue compare to its market cap?
HUMD.F fundamental statistics
Market capUS$193.05m
Earnings (TTM)-US$36.10m
Revenue (TTM)US$14.93m

12.9x

P/S Ratio

-5.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HUMD.F income statement (TTM)
RevenueCN¥108.94m
Cost of RevenueCN¥67.85m
Gross ProfitCN¥41.09m
Other ExpensesCN¥304.47m
Earnings-CN¥263.38m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin37.72%
Net Profit Margin-241.76%
Debt/Equity Ratio-721.3%

How did HUMD.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:46
End of Day Share Price 2024/09/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hua Medicine (Shanghai) Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCLSA
Bo LiCLSA
Ziyi ChenGoldman Sachs